Journal article
Complementary studies of the gastrointestinal safety of the cyclo‐oxygenase‐2‐selective inhibitor etoricoxib
Abstract
BACKGROUND: Cyclo-oxygenase-2-selective non-steroidal anti-inflammatory drugs are intended to preserve cyclo-oxygenase-1-mediated gastroprotection and platelet function, whilst inhibiting cyclo-oxygenase-2-mediated inflammation.
AIM: To assess the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib vs. non-selective non-steroidal anti-inflammatory drugs.
Authors
Hunt RH; Harper S; Callegari P; Yu C; Quan H; Evans J; James C; Bowen B; Rashid F
Journal
Alimentary Pharmacology & Therapeutics, Vol. 17, No. 2, pp. 201–210
Publisher
Wiley
Publication Date
January 2003
DOI
10.1046/j.1365-2036.2003.01407.x
ISSN
0269-2813
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAgedAged, 80 and overArthritis, RheumatoidCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDouble-Blind MethodDuodenal UlcerEtoricoxibFemaleGastrointestinal HemorrhageHumansIbuprofenIsoenzymesMaleMembrane ProteinsMiddle AgedOccult BloodOsteoarthritisProstaglandin-Endoperoxide SynthasesPyridinesStomach UlcerSulfones